What Do Cosmetics Reform Campaigners Dream Of At Night? Rep. Schakowsky Just Reintroduced It

 
• By Ryan Nelson
  
Generate a summary of this article
Listen to this article
Beta

The Safe Cosmetics and Personal Care Products Act would establish a reasonable-certainty-of-no-harm standard for FDA’s review of ingredients and require companies to share their safety information for every product with the agency, which in turn would publish it for public consumption. The bill is highly similar to Schakowsky’s previous reform proposals that divided industry and the NGO community.

Woman's dreams. Pretty girl is flying in her bed trough star sky.

Introduced Sept. 26 by Rep. Jan Schakowsky, D-Ill., the Safe Cosmetics and Personal Care Products Act of 2018 would position a number of cosmetic ingredients for bans, subject others to FDA review against a reasonable-certainty-of-no-harm standard, require safety data submissions from companies for every product they market and make that information available to the public via an FDA-managed database.

Further, cosmetics companies would be obligated to register facilities with FDA, pay fees to support the agency’s oversight activities, report...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

SpotifyApple PodcastsWebsite

More from Legislation

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By Nabil

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

Lingering Headwinds Slow Latest Results, But P&G Rebuffs Concerns About Consumer Spending

 
• By Eileen Francis

P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.

‘It's Not Sustainable For Companies To Reformulate For One State’ – PCPC’s Karin Ross

 
• By Lauren Nardella

Legislator education is key to checking state bills that overreach, says Ross, executive VP of government affairs at the Personal Care Products Council, discussing the rising tide of US state bills aimed at restricting ingredient use.

Pandemic Emergency OTC Sanitizer Makers Have 22 Weeks To Avoid Paying Monograph User Fees

 
• By Malcolm Spicer

FDA reminds companies which registered with agency solely to manufacture OTC sanitizers during COVID-19 public health emergency they will be subject to FY2025 OTC monograph user fees if they don’t delist and deregister as monograph drug manufacturers by 12 a.m. on 31 December.

More from Policy & Regulation

Stay Tuned For FDA OTC Monographs Portal Update

 
• By Malcolm Spicer

With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.

Recordati Posts Rise In OTC Sales Despite Weak Cold & Flu Season

 
• By Tom Gallen

OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.

Lingering Headwinds Slow Latest Results, But P&G Rebuffs Concerns About Consumer Spending

 
• By Eileen Francis

P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.